文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

细径全覆膜金属支架与塑料支架乳头以上逐枚置入治疗不可切除恶性肝门部胆道梗阻的多中心随机对照试验方案

Suprapapillary stent-by-stent deployment using slim fully covered metal stents versus plastic stents for unresectable malignant hilar biliary obstruction (SBSFLUX Trial): protocol for a multicenter randomized controlled trial.
PubMed 文献 · Trials · 2026-04-20

针对不可切除恶性肝门部胆道梗阻(MHBO),本研究为多中心、随机、开放标签、平行组试验,拟纳入70例Bismuth II型及以上患者,1:1随机比较乳头以上逐枚置入细径全覆膜金属支架(FCMS,直径6mm)与塑料支架(PS)的疗效与安全性。主要终点为干预后6个月无复发性胆道梗阻(RBO)率,旨在评估细径FCMS能否兼顾长期通畅性与可再干预性。

要点

  • 细径全覆膜金属支架乳头以上逐枚置入或可兼顾通畅性与可移除性。
  • 主要终点为干预后6个月无复发性胆道梗阻率,样本量70例。
  • 两组支架均带远端回收线,便于再干预时取出。

核心结论

  • 细径全覆膜金属支架乳头以上逐枚置入可能为不可切除MHBO提供更长支架通畅时间并保留再干预可行性。

研究设计与样本

  • 多中心、随机、开放标签、平行组研究,纳入不可切除MHBO且Bismuth分型II型及以上患者,1:1随机分组。
  • 目标样本量70例,每组35例。

主要发现

  • 主要终点为干预后6个月无复发性胆道梗阻率。
  • 次要终点包括至复发性胆道梗阻时间、总生存、操作成功率、临床成功率、操作时间、不良事件及再干预结局。

关键数值与推荐

  • 试验用细径全覆膜金属支架直径为6mm。
  • 全覆膜金属支架与塑料支架均配备远端回收线以助再干预时取出。

临床怎么用

  • 若试验证实有效,乳头以上逐枚置入细径全覆膜金属支架可能成为不可切除MHBO新的胆道引流选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biliary drainage is essential for patients with malignant hilar biliary obstruction (MHBO) to relieve obstructive jaundice and cholangitis and improve survival and quality of life. Uncovered metal stents (MS) are recommended for unresectable cases because of their superior duration of patency; however, their removal is technically difficult once an occlusion occurs. Plastic stents (PS) have regained attention owing to being easily removable, particularly as advances in antitumor therapies have led to prolonged survival and increased need for reintervention; however, their patency remains limited. Recently, slim fully covered MS (FCMS) have been reported to reduce the risk of side branch occlusion and may combine long-term patency with removability. This trial aims to evaluate the efficacy and safety of suprapapillary stent-by-stent (SBS) deployment of slim FCMS compared with PS deployment in patients with unresectable MHBO. METHODS: This is a multicenter, randomized, open-label, parallel-group study. Patients with unresectable MHBO classified as Bismuth type II or higher are eligible for inclusion. After informed consent is obtained, the patients will be randomized (1:1) to undergo suprapapillary SBS deployment (placement above the duodenal papilla) with either a slim FCMS or PS. The slim FCMS that will be used in this study have a 6-mm diameter, and both the FCMS and PS are equipped with a distal retrieval string to facilitate stent removal during reintervention. The primary endpoint is the rate of non-recurrent biliary obstruction (RBO) at 6 months following the intervention. Secondary endpoints include the time to RBO, overall survival, procedure success rate, clinical success rate, procedure time, adverse events, and reintervention outcomes. The target sample size is 70 patients (35 patients per group). DISCUSSION: Suprapapillary SBS deployment using slim FCMS may provide longer stent patency while preserving the feasibility of reintervention, potentially establishing a new standard biliary drainage method for unresectable MHBO. TRIAL REGISTRATION: Japan Registry of Clinical Trials: jRCT1040250073 registered on August 5, 2025. ( https://jrct.mhlw.go.jp/en-latest-detail/jRCT1040250073 ).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Inoue T, Yoshida M, Okumura F, et al. Suprapapillary stent-by-stent deployment using slim fully covered metal stents versus plastic stents for unresectable malignant hilar biliary obstruction (SBSFLUX Trial): protocol for a multicenter randomized controlled trial. Trials. 2026. PMID: 42002818. doi:10.1186/s13063-026-09733-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。